Gland Pharma Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/wl52zpeje8ithe9t2flycpm4.pdf

Key Takeaways


Base Business: Volume Decline, Margin Surge

Shyamakant Giri: "So, this year, if you see our new launches in the U.S., we have launched 27 molecules and 39 SKUs of which 30 SKUs are first-time launches in the U.S. and the gross margin there is upwards of 65% or so."

Cenexi: Inspection Fallout and Delayed Breakeven

Srinivas Sadu: "We are estimating now Q3 FY '26 could be EBITDA positive quarter. One is we mentioned about the inspection that happened last quarter. So, we lost a few weeks because of that. So that's kind of impacting the next quarter numbers a bit and last quarter numbers a bit. So that's the main reason."

U.S. Business: Shipment Timing Masks Underlying Demand

Srinivas Sadu: "Even U.S. we didn't supply Enoxa. I think there's a decline of -- I would give you a steer percentage. But 12% down in terms of quantity variance for Enoxa and Ketorolac, the other product -- 2 products."

New Growth Vectors: Biosimilars, GLP-1, and Complex Partnerships


Regulatory and Operational Milestones


Guidance & Commitments

CommitmentSpecificsTimeline
Cenexi EBITDA breakevenAchieve an EBITDA-positive quarterQ3 FY26
Cenexi full-year EBITDA positiveDeliver positive EBITDA for the full year, driven by revenue beyond EUR 200 millionFull year 2026
Cenexi Belgium lyophilizer restorationLyophilizer production restoredH1 FY26
U.S. Enoxaparin supply resumptionShipments to resume, compensating for Q3 shortfallQ4 FY25
Saudi tender shipmentDelayed hospital allotment shipments to occurQ4 FY25 or Q1 FY26
Dr. Reddy’s biologics revenueIncremental revenue from collaborationStarting FY26
MAIA complex formulation commercializationCo-developed 505(b)(2) and ANDA products commercializedBeginning FY27
Shanghai Henlius biosimilar revenueRevenue from CDMO collaboration (subject to full contract signing)FY27-FY28
GLP-1 CDMO revenueSmaller volumes begin; majority arrives laterFY26 (small); end FY27 (majority)
Pen/auto-injector line expansionAdditional 10 crore capacity commissioned2028
Cartridge capacity investment (if approved)INR 200 crore, 10 crore cartridge capacity18 months from approval
Biosimilar drug substance expansion (if approved)15 KL additional capacity at $80-100 millionUnder project evaluation

Key Metrics

MetricQ3 FY25
Consolidated revenue₹1,384.1 crore, 100 bps increase in EBITDA margin YoY
Base business (ex-Cenexi) revenue₹1,012.3 crore, 8% decrease YoY
Consolidated EBITDA₹360 crore, margin of 26% vs 23% in Q3 FY24
Base business EBITDA margin39%, vs 34% in Q3 FY24
Consolidated gross margin67%, from 61% in Q3 FY24
Base business gross margin63%, vs 56% in Q3 FY24
Net profit₹204.7 crore, up 7% YoY and 25% sequentially from Q2
PAT margin15%, improvement from 12% YoY
R&D expenditure₹43.7 crore, 4.3% of base business revenue
Cenexi revenue€4.1 crore, impacted by unannounced ANSM inspection at Fontenay
Cenexi EBITDANegative ₹31.2 crore, primarily due to the ANSM inspection
Cenexi gross margin77%, vs 75% in Q3 FY24
India market revenue₹56.2 crore, contributing 4% of total revenues
Rest of World revenue share21% of total revenues in Q3 FY25
U.S. ANDA filings (cumulative)366 filings, 312 approvals, 54 pending
Global product registrations1,736
New U.S. molecule launches in quarter13 molecules launched
Complex product portfolio progress9 filings completed of 19 targeted, 6 launched
Profit share as percentage of base business revenue11.7% in Q3
Milestone income as percentage of base business revenue10.2% in Q3
Net cash position (after Cenexi debt)₹2,412.2 crore as of Dec 31, 2024
Cash flow from operations (9M FY25)₹588.9 crore
Cenexi order bookAbove €60 million, including backlog carried from 2024
Cenexi EBITDA breakeven guidanceQ3 FY26 (previously Q4 FY25)
U.S. Enoxa market shareAbout 6%
U.S. heparin market shareAround 20%–25%
U.S. price variance QoQAbout 1% to 2% lower
One-off finance cost (GST refund matter)About ₹18 crore